MRK - Merck & Co., Inc.
77.50 -0.05 (-0.06%)
After hours: 7:47PM EDT
| Previous Close | 77.26 |
| Open | 77.00 |
| Bid | 77.29 x 1300 |
| Ask | 77.60 x 800 |
| Day's Range | 76.00 - 77.64 |
| 52 Week Range | 65.25 - 92.64 |
| Volume | 11,970,350 |
| Avg. Volume | 13,702,998 |
| Market Cap | 195.744B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 19.66 |
| EPS (TTM) | 3.94 |
| Earnings Date | Jul. 31, 2020 |
| Forward Dividend & Yield | 2.44 (3.16%) |
| Ex-Dividend Date | Jun. 12, 2020 |
| 1y Target Est | 93.94 |
- Zacks
Stock Market News for May 27, 2020
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
ReutersUS STOCKS-S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs
U.S. stocks closed higher on Tuesday on optimism about the development of coronavirus vaccines and a revival of business activity, but the S&P 500 failed to hold above the key psychological level of 3,000 points. Stocks pared gains late in the session, after Bloomberg News reported the Trump administration was weighing a range of sanctions on Chinese officials, businesses and financial institutions, reinforcing comments earlier in the day from White House adviser Larry Kudlow.
- Yahoo Finance
Stock market news live updates: S&P 500 closes at highest since March 5
Stocks jumped Tuesday, and the S&P 500 traded above 3,000 for the first time since March 5, as hopes for an effective coronavirus vaccine combined with optimism over updates around states’ reopenings. Each of the S&P 500 and Dow traded above 2% shortly after market open.
- Yahoo Finance
Coronavirus update: Novavax begins vaccine trials; Brazil reports second-highest number of cases in world
Novavax announced it would begin human trials for its coronavirus vaccine, while COVID-19 engulfs Brazil.
- Yahoo Finance
Novavax expects COVID-19 vaccine trial results in July
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
- Business Wire
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
- Business Wire
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
- Reuters
Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
Merck & Co Inc , which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus. Merck did not disclose the terms of the acquisition of Themis, a privately held company.
- Business Wire
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
ReutersMerck leaps into COVID-19 development fray with vaccine, drug deals
Merck & Co Inc, which has largely kept to the sidelines of the race for COVID-19 treatments, said it was buying Austrian vaccine maker Themis Bioscience and would collaborate with research nonprofit IAVI to develop two separate vaccines. It also announced a partnership with privately-held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19, the respiratory disease caused by the novel coronavirus. It did not disclose the terms of acquisition of Themis, a privately held company.
- Yahoo Finance
Telehealth is going to 'become the default' for patients: Ro CEO
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
- GlobeNewswire
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition — both areas of high unmet need.
- Business Wire
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
LYNPARZA Approved by FDA for Treatment of HRR Gene-Mutated mCRPC That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
- Business Wire
CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
- Zacks
Merck's (MRK) Keytruda Successful in Several Cancer Studies
Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.
- Motley Fool
Merck's Top Cancer Therapy Takes Another Big Leap Forward
Keytruda's path to becoming the world's top-selling drug looks much smoother following its latest clinical trial success.
- Motley Fool
Merck Just Made a Gamble That Smart Investors Should Bet on Too
With increasing life expectancies and aging global populations comes higher prevalence of neurodegenerative disease. Merck is betting big on being the pharma company of the future.
- Business Wire
Merck to Present at the UBS Virtual Global Healthcare Conference
Merck to Present at the UBS Virtual Global Healthcare Conference
Yahoo Finance VideoFmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development
Vanderbilt University School of Medicine,Professor of Medicine in the Division of Infectious Diseases Dr. William Schaffner joins Yahoo Finance’s Seana Smith to discuss the coronavirus, as a quarter of Americans say they are nervous about a vaccine, according to a new Reuters/Ipsos poll.
Yahoo Finance VideoJohns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.
Yahoo Finance VideoWe anticipate a U-Shaped to Swoosh-Shaped recovery: Strategist
Wells Fargo Asset Management Multi-Asset Strategist Brian Jacobsen joins Yahoo Finance’s Seana Smith to discuss the market rally amid optimism over Moderna's coronavirus vaccine data.
Yahoo Finance VideoModerna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
Yahoo Finance VideoTrump unveils vaccine effort, says country will be back on its feet with or without one
Trump revealed the newest plans to develop vaccine, but later said the country will make a comeback with or without it. Board Certified Specialist in Preventive Medicine & Public Health Dr. David Katz joins Yahoo Finance’s Seana Smith to discuss.
